Literature DB >> 12095645

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.

Kevin St P McNaught1, Roger Belizaire, Peter Jenner, C Warren Olanow, Ole Isacson.   

Abstract

The proteolytic activities of 26/20S proteasomes are impaired in the substantia nigra pars compacta (SNc) in sporadic Parkinson's disease (PD). In the present study, we examined the structural integrity of the proteasome by determining the levels of the beta- and alpha-subunits which together normally constitute the catalytic core of 26/20S proteasomes. Western blot analyzes and immunohistochemical staining revealed a major and selective loss of alpha-subunits in dopaminergic neurons of the SNc but not in other brain regions in sporadic PD. This defect is known to cause the proteasome to become unstable and prevents its assembly with resultant impairment of enzymatic activity. Thus, structural and function defects in 26/20S proteasomes may underlie protein accumulation, formation of proteinaceous Lewy bodies and dopaminergic neuronal death in the SNc in sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095645     DOI: 10.1016/s0304-3940(02)00296-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  68 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

Review 2.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

3.  Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells.

Authors:  Hui Yang; Hai-Yan Zhou; Biao Li; Guo-Zhong Niu; Sheng-Di Chen
Journal:  J Neuroimmune Pharmacol       Date:  2007-07-20       Impact factor: 4.147

4.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

5.  Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.

Authors:  Nicholas MacInnes; Mahmoud M Iravani; Elaine Perry; Margaret Piggott; Robert Perry; Peter Jenner; Clive Ballard
Journal:  J Neural Transm (Vienna)       Date:  2008-04-10       Impact factor: 3.575

6.  Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.

Authors:  Natasha Bajic; Peter Jenner; Clive G Ballard; Paul T Francis
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

7.  Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis.

Authors:  Yoshitaka Tashiro; Makoto Urushitani; Haruhisa Inoue; Masato Koike; Yasuo Uchiyama; Masaaki Komatsu; Keiji Tanaka; Maya Yamazaki; Manabu Abe; Hidemi Misawa; Kenji Sakimura; Hidefumi Ito; Ryosuke Takahashi
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

8.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

9.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.